Renal & Urology News2d
Novel Mitomycin Formulation Under Review for Bladder Cancer
The NDA has been accepted for UGN-102 for intravesical solution for low-grade intermediate-risk non-muscle invasive bladder cancer.
Cure Today3d
FDA Accepts New Drug Application for UGN-102 in Bladder Cancer
The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...
Targeted Oncology4d
FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment
UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for ...
Business Wire5d
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...
UroGen Pharma Says FDA Accepts NDA for UGN-102
UroGen Pharma new drug application for UGN-102, an investigational drug to treat certain types of bladder cancer, was approved by Food and Drug Administration. The company said on Tuesday that UGN-102 ...
Buy Rating for UroGen Pharma Amidst Key Executive Appointment and Promising Drug Pipeline
H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on URGN stock, giving a Buy rating today. Ram Selvaraju has given ...